SION-719 Added to Trikafta for Cystic Fibrosis

SION-719 Added to Trikafta for Cystic Fibrosis
22%11%0%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 27 • YES 10.6%
Sionna Therapeutics Inc. ($SION)
No stock close$44.35$40.56$36.76May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • SION $39.24May 19 • SION $37.68May 20 • SION $39.50May 21 • SION $41.75May 22 • SION $41.13May 26 • SION $42.88May 27 • SION $43.43

Will this trial show a positive result on change from baseline in sweat chloride levels?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle

Matched news2 items

All news
SION

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Topline data is on track for anticipated readout in the summer of 2026 WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today

Enrollment • Phase 2Exact NCT match: NCT07108153
SION

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary

Enrollment • Phase 2Enrollment completion Wed, Apr 1, 2026Exact NCT match: NCT07108153